Skip to content

Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination

Effect of the Expression Level of Th9 Cells and IL-9 In Poor/Non-responsiveness to Hepatitis B Vaccination

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01441609
Enrollment
94
Registered
2011-09-27
Start date
2011-08-31
Completion date
2012-05-31
Last updated
2011-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Keywords

Th9 cells, IL9, non/poor responsiveness to hepatitis B, collect blood samples after vaccination

Brief summary

An observational study will be performed in subjects aged 3-65 years old to describe the dynamic changes of cellular immunity after vaccination of hepatitis B vaccine, and to find out the expression levels of Th9 cells and IL9 in subjects with different response to the primary immunization (3 single -dose injunctions).

Detailed description

This study selected 74 volunteers which had the hepatitis B vaccine (immunization programs 0,1,6) , anti-HBs≤10mIU as the research subjects, and choose 20 volunteers which anti-HBs≥1000mIU as the control group, revaccination the groups according to the normal immunization programs, then the blood samples would be collected at 7th day, separate the PBMC and detect the expression levels of Th9 cells and IL9 by FCM, trying to find out the effects of Th9 and IL9 of non/poor -responsiveness subjects to hepatitis B.

Interventions

None listed

Sponsors

Beijing Municipal Science & Technology Commission
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL

Eligibility

Sex/Gender
ALL
Age
3 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* volunteer * between 3-60 years old * healthy * have the history of vaccination of hepatitis B. * Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. * informed consent * not allergic to the component of the vaccine

Design outcomes

Primary

MeasureTime frame
Th9 cellsblood sample of 7th day after each vaccination

Countries

China

Contacts

Primary ContactLi xuezhen
0476-5891156

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026